




Belgian Cancer Registry

## CANCER FACT SHEET 2022

### PANCREATIC CANCER

ICD-10 C25



## CONCEPTS AND ABBREVIATIONS

**Absolute numbers (N):** The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

**Average Annual Percentage Change (AAPC):** The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ( $=200 \times 1.05$ ) and 255/100,000 over 5 years ( $=200 \times (1.05)^5$ ).

**Crude Rate (CR):** The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

**ESR2013:** Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

**Net survival:** Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

**Stage:** Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8<sup>th</sup> edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

**95% CI:** 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

**ADC:** Adenocarcinoma.

**NENs:** Neuroendocrine neoplasms.



1. CANCER INCIDENCE .....	5
1.1. Pancreatic cancer incidence: by region .....	5
1.1.1. Pancreatic cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022.....	5
1.2. Pancreatic cancer incidence: by tumour stage .....	7
1.2.1. Pancreatic cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	7
1.2.2. Pancreatic cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	7
1.2.3. Pancreatic cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	8
1.3. Pancreatic cancer incidence: by tumour type.....	9
1.3.1. Pancreatic cancer incidence by tumour type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	9
1.4. Pancreatic cancer incidence: by tumour type and tumour stage.....	10
1.4.1. Pancreatic cancer incidence by tumour type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	10
2. CANCER INCIDENCE TRENDS .....	11
2.1. Pancreatic cancer incidence trends: by region.....	11
2.1.1. Pancreatic cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	11
2.1.2. Pancreatic cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	12
2.2. Pancreatic cancer incidence trends: by tumour stage .....	13
2.2.1. Pancreatic cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards...	13
2.3. Pancreatic cancer incidence trends: by age group.....	15
2.3.1. Pancreatic cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	15
2.3.2. Pancreatic cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	16
3. CANCER PREVALENCE .....	17
3.1. Pancreatic cancer prevalence: by region.....	17
3.1.1. Pancreatic cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022.....	17
4. CANCER SURVIVAL.....	18
4.1. Pancreatic cancer survival: by region .....	18
4.1.1. Pancreatic cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022.....	18
4.2. Pancreatic cancer survival: by tumour stage .....	20

4.2.1. Pancreatic cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022.....	20
4.2.2. Pancreatic cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2013-2022.....	21
4.2.3. Pancreatic cancer survival by stage and sex: number at risk and net survival probabilities, 2013-2022.....	22
5. CANCER SURVIVAL TRENDS.....	23
5.1. Pancreatic cancer survival trends: by tumour stage.....	23
5.1.1. Pancreatic cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022.....	23
5.2. Pancreatic cancer survival trends: by tumour type and tumour stage.....	25
5.2.1. Pancreatic cancer survival trends by tumour type, stage and sex: number at risk and net survival probabilities, 2008-2022.....	25
6. CANCER MORTALITY.....	28
6.1. Pancreatic cancer mortality: by region.....	28
6.1.1. Pancreatic cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021.....	28
7. CANCER MORTALITY TRENDS.....	30
7.1. Pancreatic cancer mortality trends: by region.....	30
7.1.1. Pancreatic cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021.....	30
7.1.2. Pancreatic cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021.....	31



# 1. CANCER INCIDENCE



## 1.1. Pancreatic cancer incidence: by region

1.1.1. Pancreatic cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
<b>Belgium</b>	0	0	0	1	1	2	3	3	15	21	43	97	155	165	204	182	127	77	34	4	1,134	21.3
	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.5]	[0.8]	[0.8]	[3.9]	[5.6]	[10.9]	[24.0]	[42.0]	[52.8]	[77.3]	[95.7]	[100.3]	[98.2]	[113.2]	[68.4]	[19.9]	(20.1; 22.5)
Brussels	0	0	0	0	0	0	1	1	1	3	3	4	10	7	18	10	7	7	1	0	73	19.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.9]	[2.1]	[2.2]	[6.9]	[7.4]	[11.5]	[35.8]	[33.1]	[109.0]	[82.1]	[86.7]	[137.6]	[46.1]	[0.0]	[12.2]	(14.9; 24.1)
Flanders	0	0	0	1	0	2	2	1	9	11	28	55	85	99	120	113	82	55	20	3	686	20.6
	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[1.0]	[0.9]	[0.5]	[4.1]	[5.2]	[12.1]	[22.5]	[37.8]	[51.6]	[74.2]	[91.5]	[98.1]	[104.8]	[100.4]	[79.4]	[20.7]	(19.1; 22.2)
Wallonia	0	0	0	0	1	0	0	1	5	7	12	38	60	59	66	59	38	15	13	1	375	23.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[0.0]	[0.9]	[4.3]	[5.8]	[9.6]	[30.4]	[51.6]	[59.4]	[76.9]	[108.0]	[108.7]	[71.8]	[163.9]	[65.0]	[20.9]	(20.8; 25.6)
Females																						
<b>Belgium</b>	0	0	3	2	1	2	3	5	11	22	37	75	117	129	168	179	150	97	38	6	1,045	16.4
	[0.0]	[0.0]	[0.9]	[0.6]	[0.3]	[0.6]	[0.8]	[1.3]	[2.9]	[6.0]	[9.6]	[18.8]	[31.1]	[38.8]	[56.9]	[77.5]	[84.2]	[72.0]	[54.8]	[29.2]	[17.8]	(15.4; 17.4)
Brussels	0	0	1	0	0	0	0	1	1	2	2	6	16	10	13	13	9	5	2	1	82	16.7
	[0.0]	[0.0]	[2.7]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[2.2]	[5.0]	[5.4]	[17.8]	[53.8]	[40.2]	[61.0]	[75.4]	[69.1]	[49.7]	[34.6]	[48.5]	[13.2]	(13.0; 20.3)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Flanders	0	0	2	2	0	0	3	0	4	14	23	34	70	72	102	123	88	55	23	4	619	16.1
	[0.0]	[0.0]	[1.1]	[1.1]	[0.0]	[0.0]	[1.4]	[0.0]	[1.8]	[6.8]	[10.2]	[14.3]	[31.2]	[36.4]	[58.7]	[86.0]	[78.6]	[64.6]	[54.0]	[33.1]	[18.3]	(14.9; 17.4)
Wallonia	0	0	0	0	1	2	0	4	6	6	12	35	31	47	53	43	53	37	13	1	344	16.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[1.9]	[0.0]	[3.5]	[5.2]	[5.0]	[9.7]	[27.6]	[25.3]	[42.7]	[52.9]	[60.7]	[99.7]	[93.7]	[61.8]	[15.7]	[18.4]	(15.1; 18.8)

## 1.2. Pancreatic cancer incidence: by tumour stage

1.2.1. Pancreatic cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	55 [1.6]	105 [11.1]	83 [19.3]	243 [4.3]	4.6 (4.0; 5.1)	49 [1.5]	79 [7.9]	103 [16.2]	233 [4.0]	3.7 (3.2; 4.1)
II	35 [1.0]	85 [9.0]	53 [12.3]	173 [3.0]	3.2 (2.7; 3.7)	20 [0.6]	60 [6.0]	49 [7.7]	130 [2.2]	2.1 (1.7; 2.4)
III	20 [0.6]	50 [5.3]	46 [10.7]	116 [2.0]	2.2 (1.8; 2.6)	14 [0.4]	56 [5.6]	55 [8.7]	125 [2.1]	2.0 (1.6; 2.3)
IV	69 [2.1]	256 [27.1]	208 [48.2]	533 [9.3]	10.0 (9.1; 10.8)	64 [1.9]	191 [19.0]	213 [33.6]	468 [8.0]	7.3 (6.7; 8.0)
X/NA	7 [0.2]	28 [3.0]	34 [7.9]	69 [1.2]	1.3 (1.0; 1.7)	11 [0.3]	28 [2.8]	50 [7.9]	89 [1.5]	1.4 (1.1; 1.7)

1.2.2. Pancreatic cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	21 [0.6]	52 [5.5]	18 [4.2]	91 [1.6]	1.7 (1.3; 2.0)	26 [0.8]	42 [4.2]	17 [2.7]	86 [1.5]	1.4 (1.1; 1.7)
II	22 [0.7]	63 [6.7]	32 [7.4]	117 [2.0]	2.1 (1.8; 2.5)	21 [0.6]	40 [4.0]	20 [3.2]	82 [1.4]	1.4 (1.1; 1.7)
III	21 [0.6]	45 [4.8]	15 [3.5]	81 [1.4]	1.5 (1.1; 1.8)	9 [0.3]	30 [3.0]	22 [3.5]	61 [1.0]	1.0 (0.7; 1.3)
IV	16 [0.5]	62 [6.6]	47 [10.9]	125 [2.2]	2.3 (1.9; 2.7)	26 [0.8]	59 [5.9]	34 [5.4]	119 [2.0]	2.0 (1.6; 2.3)
X/NA	106 [3.2]	302 [31.9]	312 [72.4]	720 [12.6]	13.7 (12.7; 14.7)	76 [2.3]	243 [24.2]	377 [59.5]	697 [11.9]	10.6 (9.8; 11.4)

1.2.3. Pancreatic cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
<b>I</b>	46 [1.4]	81 [8.6]	60 [13.9]	187 [3.3]	3.5 (3.0; 4.0)	39 [1.2]	61 [6.1]	87 [13.7]	189 [3.2]	2.9 (2.5; 3.4)
<b>II</b>	33 [1.0]	81 [8.6]	67 [15.5]	181 [3.2]	3.4 (2.9; 3.9)	25 [0.8]	63 [6.3]	58 [9.1]	147 [2.5]	2.4 (2.0; 2.7)
<b>III</b>	33 [1.0]	81 [8.6]	58 [13.5]	172 [3.0]	3.2 (2.7; 3.7)	20 [0.6]	69 [6.9]	68 [10.7]	157 [2.7]	2.5 (2.1; 2.9)
<b>IV</b>	72 [2.2]	262 [27.7]	212 [49.2]	546 [9.6]	10.2 (9.4; 11.1)	66 [2.0]	203 [20.2]	218 [34.4]	487 [8.3]	7.6 (7.0; 8.3)
<b>X/NA</b>	2 [0.1]	19 [2.0]	27 [6.3]	48 [0.8]	1.0 (0.7; 1.2)	8 [0.2]	18 [1.8]	39 [6.2]	65 [1.1]	1.0 (0.7; 1.2)



### 1.3. Pancreatic cancer incidence: by tumour type

1.3.1. *Pancreatic cancer incidence by tumour type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022*

type	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
<b>ADC</b>	118 [3.5]	421 [44.5]	283 [65.6]	822 [14.4]	15.3 (14.2; 16.3)	100 [3.0]	339 [33.7]	322 [50.8]	761 [13.0]	12.1 (11.3; 13.0)
<b>NENs</b>	49 [1.5]	65 [6.9]	28 [6.5]	142 [2.5]	2.6 (2.2; 3.0)	41 [1.2]	35 [3.5]	25 [3.9]	103 [1.8]	1.7 (1.4; 2.0)
<b>Other and unspecified</b>	19 [0.6]	38 [4.0]	113 [26.2]	170 [3.0]	3.4 (2.9; 3.9)	17 [0.5]	40 [4.0]	123 [19.4]	181 [3.1]	2.6 (2.2; 3.0)

## 1.4. Pancreatic cancer incidence: by tumour type and tumour stage

1.4.1. Pancreatic cancer incidence by tumour type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

type	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-59	60-74	75+	All ages	15-59	60-74	75+	All ages		
<b>ADC</b>	<b>I</b>	19 [0.6]	46 [4.9]	29 [6.7]	94 [1.6]	1.8 (1.4; 2.1)	12 [0.4]	36 [3.6]	42 [6.6]	90 [1.5]	1.4 (1.1; 1.7)
	<b>II</b>	20 [0.6]	64 [6.8]	53 [12.3]	137 [2.4]	2.6 (2.1; 3.0)	15 [0.5]	51 [5.1]	40 [6.3]	106 [1.8]	1.7 (1.4; 2.0)
	<b>III</b>	23 [0.7]	69 [7.3]	42 [9.7]	134 [2.3]	2.5 (2.1; 2.9)	18 [0.5]	61 [6.1]	53 [8.4]	132 [2.2]	2.1 (1.8; 2.5)
	<b>IV</b>	54 [1.6]	229 [24.2]	143 [33.2]	426 [7.5]	7.9 (7.1; 8.6)	53 [1.6]	178 [17.7]	160 [25.2]	391 [6.7]	6.2 (5.6; 6.8)
	<b>X/NA</b>	2 [0.1]	13 [1.4]	16 [3.7]	31 [0.5]	0.6 (0.4; 0.8)	2 [0.1]	13 [1.3]	27 [4.3]	42 [0.7]	0.6 (0.4; 0.8)
<b>NENs</b>	<b>I</b>	17 [0.5]	24 [2.5]	8 [1.9]	49 [0.9]	0.9 (0.6; 1.1)	21 [0.6]	16 [1.6]	13 [2.1]	52 [0.9]	0.9 (0.6; 1.1)
	<b>II</b>	10 [0.3]	13 [1.4]	4 [0.9]	27 [0.5]	0.5 (0.3; 0.7)	7 [0.2]	5 [0.5]	4 [0.6]	16 [0.3]	0.3 (0.1; 0.4)
	<b>III</b>	9 [0.3]	10 [1.1]	2 [0.5]	21 [0.4]	0.4 (0.2; 0.5)	1 [0.0]	5 [0.5]	1 [0.2]	7 [0.1]	0.1 (0.0; 0.2)
	<b>IV</b>	13 [0.4]	15 [1.6]	12 [2.8]	40 [0.7]	0.7 (0.5; 1.0)	8 [0.2]	7 [0.7]	6 [0.9]	21 [0.4]	0.3 (0.2; 0.5)
	<b>X/NA</b>	0 [0.0]	3 [0.3]	2 [0.5]	5 [0.1]	0.1 (0.0; 0.2)	4 [0.1]	2 [0.2]	1 [0.2]	7 [0.1]	0.1 (0.0; 0.2)
<b>Other and unspecified</b>	<b>I</b>	10 [0.3]	11 [1.2]	23 [5.3]	44 [0.8]	0.9 (0.6; 1.1)	6 [0.2]	9 [0.9]	32 [5.0]	47 [0.8]	0.6 (0.5; 0.8)
	<b>II</b>	3 [0.1]	4 [0.4]	10 [2.3]	17 [0.3]	0.3 (0.2; 0.5)	3 [0.1]	7 [0.7]	14 [2.2]	25 [0.4]	0.4 (0.2; 0.5)
	<b>III</b>	1 [0.0]	2 [0.2]	14 [3.2]	17 [0.3]	0.4 (0.2; 0.5)	1 [0.0]	3 [0.3]	14 [2.2]	18 [0.3]	0.2 (0.1; 0.4)
	<b>IV</b>	5 [0.1]	18 [1.9]	57 [13.2]	80 [1.4]	1.6 (1.2; 2.0)	5 [0.2]	18 [1.8]	52 [8.2]	75 [1.3]	1.1 (0.8; 1.3)
	<b>X/NA</b>	0 [0.0]	3 [0.3]	9 [2.1]	12 [0.2]	0.3 (0.1; 0.4)	2 [0.1]	3 [0.3]	11 [1.7]	16 [0.3]	0.2 (0.1; 0.4)

## 2. CANCER INCIDENCE TRENDS



### 2.1. Pancreatic cancer incidence trends: by region

2.1.1. Pancreatic cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
Belgium	<b>N</b>	572	545	614	647	597	713	788	782	814	860	873	890	900	984	1,054	1,052	1,045	1,179	1,134			
	<b>CR</b>	11.2	10.7	11.9	12.5	11.4	13.5	14.8	14.6	15.0	15.8	15.9	16.2	16.3	17.7	18.8	18.7	18.5	20.8	19.9			
	<b>ESR2013</b>	14.1	13.0	14.8	14.9	13.8	16.2	17.8	17.3	17.7	18.5	18.4	18.4	18.6	19.8	21.1	20.4	20.2	22.3	21.3	2.7 (2.3; 3.2)	2004-2022	
Brussels	<b>N</b>	50	39	39	62	66	63	69	62	73	63	68	84	67	83	75	77	69	86	73			
	<b>CR</b>	10.4	8.1	8.0	12.5	13.1	12.2	13.1	11.4	13.2	11.2	12.0	14.7	11.6	14.3	12.8	13.0	11.5	14.4	12.2			
	<b>ESR2013</b>	14.8	11.8	11.2	18.7	19.7	18.9	19.7	17.4	21.0	17.9	18.9	22.7	18.2	22.5	20.2	20.0	17.8	22.7	19.5	2.3 (1.1; 3.6)	2004-2022	
																					5.6 (2.4; 8.9)	2004-2012	
																						-0.2 (-2.5; 2.2)	2013-2022
Flanders	<b>N</b>	335	325	359	354	356	397	443	430	484	497	489	513	545	568	663	622	619	682	686			
	<b>CR</b>	11.3	10.9	12.0	11.7	11.7	13.0	14.4	13.8	15.4	15.8	15.4	16.1	17.0	17.6	20.5	19.1	18.9	20.7	20.7			
	<b>ESR2013</b>	13.7	12.9	14.2	13.2	13.5	14.7	16.3	15.3	17.0	17.3	16.6	17.1	18.1	18.4	21.5	19.5	19.3	20.8	20.6	2.8 (2.4; 3.2)	2004-2022	
Wallonia	<b>N</b>	187	181	216	231	175	253	276	290	257	300	316	293	288	333	316	353	357	411	375			
	<b>CR</b>	11.4	11.0	13.0	13.9	10.4	15.0	16.2	16.9	14.9	17.3	18.1	16.7	16.4	18.9	17.9	19.9	20.0	23.0	20.9			
	<b>ESR2013</b>	14.7	13.7	16.9	17.4	13.2	18.6	20.3	21.2	18.3	21.1	21.8	20.0	19.4	22.2	20.5	22.3	22.6	25.4	23.2	2.7 (1.8; 3.6)	2004-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Pancreatic cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
Belgium	<b>N</b>	499	531	575	546	581	663	737	758	749	814	848	892	903	899	990	1,001	1,027	1,114	1,045			
	<b>CR</b>	9.4	10.0	10.7	10.1	10.7	12.1	13.3	13.6	13.3	14.4	14.9	15.6	15.8	15.6	17.1	17.2	17.6	19.1	17.8			
	<b>ESR2013</b>	9.6	10.1	10.8	10.2	10.6	12.0	13.1	13.4	13.1	14.0	14.6	15.1	15.1	15.0	16.2	16.3	16.4	17.7	16.4	3.3 (3.0; 3.7)	2004-2022	
																					4.4 (3.7; 5.1)	2004-2014	
																						2.0 (1.1; 2.9)	2015-2022
Brussels	<b>N</b>	43	35	68	39	59	63	69	70	67	69	79	73	82	86	72	74	71	84	82			
	<b>CR</b>	8.3	6.7	12.9	7.3	10.9	11.4	12.3	12.1	11.4	11.6	13.2	12.1	13.5	14.1	11.8	12.0	11.4	13.5	13.2			
	<b>ESR2013</b>	9.1	7.7	15.0	8.2	12.5	13.6	14.9	13.8	13.8	13.5	16.5	14.9	16.4	17.6	14.4	14.6	14.4	16.8	16.7	3.1 (1.5; 4.6)	2004-2022	
Flanders	<b>N</b>	283	311	301	319	315	381	416	416	445	463	499	492	517	508	616	566	625	672	619			
	<b>CR</b>	9.3	10.2	9.8	10.3	10.1	12.1	13.1	13.0	13.8	14.3	15.4	15.1	15.8	15.4	18.6	17.0	18.7	20.0	18.3			
	<b>ESR2013</b>	9.3	10.1	9.7	10.1	9.8	11.6	12.5	12.4	13.1	13.4	14.4	14.0	14.5	13.9	16.9	15.3	16.5	17.6	16.1	3.6 (3.0; 4.1)	2004-2022	
Wallonia	<b>N</b>	173	185	206	188	207	219	252	272	237	282	270	327	304	305	302	361	331	358	344			
	<b>CR</b>	9.9	10.6	11.7	10.6	11.6	12.3	14.0	15.0	13.0	15.4	14.7	17.8	16.5	16.5	16.3	19.4	17.8	19.2	18.4			
	<b>ESR2013</b>	10.2	10.9	11.8	10.8	11.7	12.6	14.0	15.2	13.0	15.1	14.3	17.2	15.9	16.2	15.4	18.6	16.7	18.0	16.9	3.1 (2.4; 3.7)	2004-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.2. Pancreatic cancer incidence trends: by tumour stage

2.2.1. Pancreatic cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Stage	Males							Females							
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
<b>I</b>	<b>N</b>	128	171	137	178	187			136	149	156	216	189		
	<b>CR</b>	2.3	3.0	2.4	3.1	3.3			2.4	2.6	2.7	3.7	3.2		
	<b>ESR2013</b>	2.5	3.3	2.6	3.3	3.5	8.7 (6.6; 10.8)	2004-2022	2.2	2.4	2.5	3.4	2.9	10.2 (8.8; 11.6)	2004-2022
<b>II</b>	<b>N</b>	166	173	168	176	181			154	160	150	169	147		
	<b>CR</b>	3.0	3.1	3.0	3.1	3.2			2.7	2.8	2.6	2.9	2.5		
	<b>ESR2013</b>	3.3	3.4	3.3	3.3	3.4	1.6 (0.7; 2.6)	2004-2022	2.5	2.6	2.4	2.7	2.4	1.0 (0.1; 2.0)	2004-2022
						7.7 (5.1; 10.3)	2004-2012						6.3 (4.4; 8.3)	2004-2014	
						-2.9 (-4.7; -1.1)	2013-2022						-5.3 (-7.5; -3.0)	2015-2022	
<b>III</b>	<b>N</b>	143	146	160	175	172			126	119	152	167	157		
	<b>CR</b>	2.6	2.6	2.8	3.1	3.0			2.2	2.1	2.6	2.9	2.7		
	<b>ESR2013</b>	2.8	2.8	3.1	3.3	3.2	8.7 (6.8; 10.7)	2004-2022	2.1	2.0	2.5	2.7	2.5	7.4 (5.6; 9.2)	2004-2022
						5.2 (2.3; 8.1)	2004-2016						3.2 (0.6; 5.9)	2004-2016	
						16.2 (9.3; 23.5)	2017-2022						16.3 (9.9; 23.0)	2017-2022	
<b>IV</b>	<b>N</b>	499	475	519	600	546			462	489	514	525	487		
	<b>CR</b>	8.9	8.4	9.2	10.6	9.6			8.0	8.4	8.8	9.0	8.3		
	<b>ESR2013</b>	10.0	9.2	10.0	11.3	10.2	4.9 (4.2; 5.6)	2004-2022	7.6	8.0	8.2	8.4	7.6	5.7 (5.0; 6.3)	2004-2022
													6.8 (5.9; 7.8)	2004-2016	
													3.4 (1.3; 5.4)	2017-2022	
<b>X/NA</b>	<b>N</b>	118	87	61	50	48			112	84	55	37	65		
	<b>CR</b>	2.1	1.5	1.1	0.9	0.8			1.9	1.4	0.9	0.6	1.1		

Stage	Males							Females						
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
ESR2013	2.4	1.7	1.2	1.0	1.0	-8.3 (-9.2; -7.3)	2004-2022	1.7	1.3	0.8	0.5	1.0	-8.1 (-9.7; -6.5)	2004-2022
						-2.4 (-4.3; -0.3)	2004-2014						-1.5 (-4.4; 1.5)	2004-2015
						-15.2 (-17.4; -12.9)	2015-2022						-17.7 (-21.7; -13.5)	2016-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.3. Pancreatic cancer incidence trends: by age group

2.3.1. Pancreatic cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
<b>15-59</b>	<b>N</b>	133	140	145	169	137	161	157	176	166	166	195	180	162	183	185	201	186	219	186			
	<b>CR</b>	4.2	4.4	4.5	5.2	4.2	4.9	4.8	5.3	5.0	5.0	5.9	5.4	4.9	5.5	5.5	6.0	5.6	6.6	5.6			
	<b>ESR2013</b>	4.4	4.6	4.7	5.4	4.3	5.1	4.9	5.4	5.0	5.0	5.8	5.4	4.8	5.4	5.4	5.9	5.4	6.4	5.4	1.3 (0.7; 1.9)	2004-2022	
<b>60-74</b>	<b>N</b>	285	250	267	287	277	331	350	351	392	413	378	417	396	462	508	522	475	562	524			
	<b>CR</b>	41.9	36.5	38.9	41.0	38.9	45.5	47.2	46.4	51.0	52.7	47.4	51.3	47.6	53.9	57.8	58.1	51.8	60.1	55.4			
	<b>ESR2013</b>	41.6	36.3	38.9	41.4	39.3	46.7	48.5	48.2	51.9	54.6	49.3	52.6	49.1	55.1	59.0	59.2	52.7	61.0	56.3	2.6 (2.0; 3.3)	2004-2022	
																					4.3 (2.2; 6.4)	2004-2010	
																						1.8 (0.9; 2.8)	2011-2022
<b>75+</b>	<b>N</b>	154	155	202	191	183	221	281	255	256	281	300	293	342	339	361	328	383	398	424			
	<b>CR</b>	52.5	51.2	64.3	58.6	54.3	64.0	79.4	70.6	69.4	74.7	78.2	74.8	86.6	85.9	90.9	81.2	92.6	95.7	98.3			
	<b>ESR2013</b>	51.1	48.4	62.3	54.8	53.4	61.4	76.7	68.3	69.0	72.3	75.7	73.2	85.0	84.3	90.6	79.8	92.2	94.5	98.3	3.7 (3.0; 4.4)	2004-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.2. Pancreatic cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
<b>15-59</b>	<b>N</b>	85	102	99	97	106	117	129	142	136	154	134	157	179	148	173	158	144	172	158		
	<b>CR</b>	2.7	3.2	3.1	3.0	3.3	3.6	4.0	4.4	4.2	4.7	4.1	4.8	5.4	4.5	5.3	4.8	4.4	5.2	4.8		
	<b>ESR2013</b>	2.8	3.4	3.2	3.1	3.4	3.7	4.0	4.4	4.2	4.7	4.0	4.7	5.3	4.4	5.2	4.7	4.2	5.1	4.7	2.9 (2.2; 3.6)	2004-2022
																					5.2 (3.6; 6.8)	2004-2013
																					0.6 (-0.9; 2.1)	2014-2022
<b>60-74</b>	<b>N</b>	207	227	233	231	221	268	297	274	279	297	346	332	349	359	387	417	417	460	414		
	<b>CR</b>	26.7	29.3	30.2	29.6	28.0	33.5	36.7	33.3	33.4	35.1	40.3	38.1	39.1	39.1	41.2	43.5	42.7	46.3	41.2		
	<b>ESR2013</b>	26.1	28.7	29.9	29.4	28.2	33.9	36.9	34.0	34.0	35.8	41.2	39.1	39.5	39.9	41.6	43.8	43.0	46.4	41.5	2.9 (2.4; 3.4)	2004-2022
<b>75+</b>	<b>N</b>	206	202	243	218	254	277	311	342	334	363	368	401	375	392	430	425	466	481	470		
	<b>CR</b>	39.6	38.0	44.6	39.1	44.6	47.9	53.0	57.6	55.7	60.1	60.3	65.0	60.8	64.0	70.4	69.2	75.1	77.7	74.1		
	<b>ESR2013</b>	39.7	38.2	44.3	38.8	44.2	46.9	52.0	58.2	56.0	59.0	60.4	65.1	60.8	64.5	70.7	70.2	75.8	78.2	75.3	4.2 (3.7; 4.7)	2004-2022
																					5.4 (4.2; 6.6)	2004-2012
																					3.3 (2.3; 4.2)	2013-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



### 3. CANCER PREVALENCE



#### 3.1. Pancreatic cancer prevalence: by region

3.1.1. *Pancreatic cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022*

Region		Males				Females			
		1-year	5-year	10-year	15-year	1-year	5-year	10-year	15-year
Belgium	<b>N</b>	740	1,721	2,074	2,290	656	1,542	1,952	2,154
	<b>CR</b>	12.8	29.9	36.0	39.7	11.1	26.0	32.9	36.3
	<b>ESR2013</b>	13.5	31.3	37.8	41.7	10.4	24.7	31.2	34.4
Brussels	<b>N</b>	50	102	121	135	53	119	151	162
	<b>CR</b>	8.2	16.8	19.9	22.2	8.4	18.8	23.9	25.6
	<b>ESR2013</b>	12.8	26.0	31.2	34.5	10.6	23.3	29.6	31.8
Flanders	<b>N</b>	450	1,077	1,313	1,437	391	952	1,197	1,318
	<b>CR</b>	13.4	32.1	39.2	42.9	11.4	27.8	35.0	38.5
	<b>ESR2013</b>	13.2	31.6	38.6	42.3	10.3	25.3	31.8	35.0
Wallonia	<b>N</b>	240	542	640	718	212	471	604	674
	<b>CR</b>	13.3	30.1	35.5	39.9	11.3	25.0	32.1	35.8
	<b>ESR2013</b>	14.4	32.1	37.9	42.7	10.6	23.8	30.5	34.0

## 4. CANCER SURVIVAL



### 4.1. Pancreatic cancer survival: by region

#### 4.1.1. Pancreatic cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	19,416	41.9% (41.2%; 42.6%)	18.7% (18.2%; 19.4%)	14.0% (13.4%; 14.6%)	11.5% (10.6%; 12.4%)
Males						
Belgium	All ages	9,921	42.2% (41.2%; 43.2%)	19.1% (18.3%; 20.0%)	14.3% (13.4%; 15.2%)	11.2% (9.8%; 12.7%)
	15-59	1,853	55.7% (53.5%; 58.1%)	28.0% (26.0%; 30.2%)	23.3% (21.3%; 25.5%)	18.0% (15.4%; 20.9%)
	60-74	4,635	46.8% (45.4%; 48.3%)	21.2% (20.0%; 22.5%)	15.4% (14.2%; 16.7%)	12.6% (11.0%; 14.4%)
	75+	3,433	28.7% (27.2%; 30.4%)	11.5% (10.3%; 12.8%)	7.9% (6.6%; 9.4%)	5.7% (3.4%; 9.6%)
Brussels	All ages	734	40.0% (36.6%; 43.8%)	13.6% (11.1%; 16.7%)	8.9% (6.7%; 11.9%)	7.6% (5.3%; 10.9%)
	15-59	166	47.8% (40.8%; 56.1%)	14.6% (9.9%; 21.6%)	9.7% (5.7%; 16.5%)	8.8% (5.0%; 15.7%)
	60-74	340	44.9% (39.8%; 50.6%)	19.4% (15.4%; 24.6%)	12.9% (9.3%; 18.0%)	10.4% (6.6%; 16.5%)
	75+	228	27.1% (21.7%; 33.9%)	4.0% (1.8%; 8.7%)	1.6% (0.4%; 6.6%)	FU<10y
Flanders	All ages	5,858	43.6% (42.3%; 44.9%)	20.8% (19.7%; 22.0%)	16.1% (15.0%; 17.4%)	12.6% (10.7%; 15.0%)
	15-59	1,014	57.5% (54.5%; 60.6%)	31.6% (28.7%; 34.7%)	26.1% (23.2%; 29.2%)	20.4% (16.4%; 25.2%)
	60-74	2,675	49.8% (47.9%; 51.8%)	23.3% (21.6%; 25.1%)	17.9% (16.2%; 19.7%)	14.2% (12.0%; 16.9%)
	75+	2,169	29.5% (27.6%; 31.6%)	12.9% (11.3%; 14.7%)	9.3% (7.6%; 11.4%)	6.9% (3.9%; 12.3%)
Wallonia	All ages	3,329	40.3% (38.6%; 42.0%)	17.2% (15.9%; 18.7%)	12.2% (10.9%; 13.6%)	9.4% (7.8%; 11.3%)

Net Survival Probability, 2013-2022							
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	<b>15-59</b>	673	55.0% (51.3%; 58.9%)	26.0% (22.7%; 29.7%)	22.4% (19.2%; 26.0%)	16.3% (13.0%; 20.6%)	
	<b>60-74</b>	1,620	42.4% (40.0%; 44.9%)	18.1% (16.2%; 20.2%)	11.8% (10.1%; 13.8%)	10.4% (8.3%; 13.1%)	
	<b>75+</b>	1,036	27.4% (24.7%; 30.4%)	10.1% (8.2%; 12.5%)	6.1% (4.3%; 8.6%)	4.3% (2.0%; 9.0%)	
Females							
<b>Belgium</b>	<b>All ages</b>	9,495	41.5% (40.5%; 42.5%)	18.4% (17.5%; 19.2%)	13.7% (12.9%; 14.6%)	11.7% (10.5%; 12.9%)	
	<b>15-59</b>	1,565	66.1% (63.8%; 68.5%)	37.0% (34.6%; 39.5%)	31.1% (28.7%; 33.6%)	27.9% (25.2%; 30.7%)	
	<b>60-74</b>	3,764	47.7% (46.1%; 49.4%)	20.1% (18.8%; 21.5%)	14.2% (13.0%; 15.5%)	11.6% (10.2%; 13.2%)	
	<b>75+</b>	4,166	26.6% (25.2%; 28.0%)	9.8% (8.8%; 10.9%)	6.7% (5.7%; 7.9%)	5.6% (3.8%; 8.1%)	
Brussels	<b>All ages</b>	767	40.1% (36.7%; 43.9%)	16.8% (14.2%; 19.9%)	13.5% (11.0%; 16.6%)	11.2% (8.2%; 15.2%)	
	<b>15-59</b>	156	66.9% (59.9%; 74.8%)	38.6% (31.5%; 47.3%)	31.1% (24.0%; 40.4%)	29.5% (22.1%; 39.5%)	
	<b>60-74</b>	280	46.4% (40.8%; 52.7%)	19.5% (15.1%; 25.1%)	16.5% (12.2%; 22.2%)	15.4% (10.8%; 21.9%)	
	<b>75+</b>	331	22.4% (18.2%; 27.6%)	4.5% (2.6%; 7.7%)	3.0% (1.4%; 6.2%)	1.1% (0.2%; 4.9%)	
Flanders	<b>All ages</b>	5,556	42.8% (41.5%; 44.2%)	19.6% (18.5%; 20.7%)	14.7% (13.6%; 15.9%)	12.4% (10.7%; 14.3%)	
	<b>15-59</b>	849	67.4% (64.3%; 70.6%)	37.6% (34.4%; 41.2%)	32.0% (28.8%; 35.6%)	28.5% (25.0%; 32.5%)	
	<b>60-74</b>	2,182	49.1% (47.0%; 51.3%)	21.7% (19.9%; 23.6%)	15.0% (13.4%; 16.9%)	12.4% (10.5%; 14.7%)	
	<b>75+</b>	2,525	29.1% (27.3%; 31.0%)	11.6% (10.3%; 13.2%)	8.5% (7.0%; 10.1%)	6.7% (4.1%; 10.9%)	
Wallonia	<b>All ages</b>	3,172	39.5% (37.8%; 41.3%)	16.7% (15.3%; 18.1%)	12.0% (10.8%; 13.4%)	10.6% (9.1%; 12.3%)	
	<b>15-59</b>	560	64.1% (60.2%; 68.2%)	35.4% (31.5%; 39.8%)	29.4% (25.5%; 33.8%)	26.4% (22.2%; 31.4%)	
	<b>60-74</b>	1,302	45.7% (43.0%; 48.5%)	17.6% (15.6%; 20.0%)	12.3% (10.5%; 14.5%)	9.6% (7.5%; 12.2%)	
	<b>75+</b>	1,310	22.9% (20.6%; 25.4%)	7.8% (6.3%; 9.6%)	4.5% (3.2%; 6.3%)	5.0% (3.2%; 8.0%)	

## 4.2. Pancreatic cancer survival: by tumour stage

### 4.2.1. Pancreatic cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total</b>	19,416	41.9% (41.2%; 42.6%)	25.1% (24.5%; 25.8%)	18.7% (18.2%; 19.4%)	15.8% (15.2%; 16.4%)	14.0% (13.4%; 14.6%)	11.5% (10.6%; 12.4%)
<b>Males</b>							
<b>All</b>	9,921	42.2% (41.2%; 43.2%)	25.3% (24.4%; 26.2%)	19.1% (18.3%; 20.0%)	16.2% (15.4%; 17.1%)	14.3% (13.4%; 15.2%)	11.2% (9.8%; 12.7%)
<b>I</b>	1,409	73.3% (70.8%; 75.8%)	55.0% (52.2%; 57.9%)	46.9% (44.0%; 50.0%)	41.4% (38.2%; 44.8%)	38.5% (35.1%; 42.2%)	35.2% (29.0%; 42.6%)
<b>II</b>	1,329	59.5% (56.8%; 62.3%)	38.0% (35.3%; 40.9%)	28.2% (25.6%; 31.0%)	23.5% (20.9%; 26.3%)	18.7% (16.1%; 21.7%)	14.5% (10.5%; 19.8%)
<b>III</b>	846	48.2% (44.8%; 51.8%)	22.1% (19.4%; 25.3%)	13.7% (11.3%; 16.5%)	10.5% (8.3%; 13.2%)	9.0% (6.8%; 11.8%)	7.2% (4.4%; 11.8%)
<b>IV</b>	4,531	23.3% (22.0%; 24.5%)	9.0% (8.1%; 9.9%)	4.8% (4.2%; 5.6%)	3.3% (2.7%; 3.9%)	2.7% (2.2%; 3.3%)	1.5% (1.0%; 2.2%)
<b>X/NA</b>	1,816	50.1% (47.8%; 52.5%)	35.3% (33.0%; 37.7%)	29.0% (26.8%; 31.3%)	26.0% (23.8%; 28.4%)	23.3% (21.0%; 25.7%)	18.1% (14.9%; 22.1%)
<b>Females</b>							
<b>All</b>	9,495	41.5% (40.5%; 42.5%)	24.9% (24.0%; 25.8%)	18.4% (17.5%; 19.2%)	15.4% (14.6%; 16.3%)	13.7% (12.9%; 14.6%)	11.7% (10.5%; 12.9%)
<b>I</b>	1,512	68.3% (65.9%; 70.8%)	50.8% (48.1%; 53.5%)	42.3% (39.6%; 45.2%)	38.1% (35.2%; 41.2%)	34.1% (31.2%; 37.4%)	32.1% (27.6%; 37.2%)
<b>II</b>	1,182	54.7% (51.9%; 57.8%)	33.1% (30.4%; 36.0%)	23.7% (21.2%; 26.5%)	18.9% (16.5%; 21.7%)	16.5% (14.0%; 19.4%)	12.9% (9.7%; 17.1%)
<b>III</b>	827	46.3% (42.9%; 49.9%)	22.3% (19.5%; 25.5%)	12.1% (9.9%; 14.8%)	7.4% (5.5%; 10.0%)	5.1% (3.4%; 7.7%)	FU<10y
<b>IV</b>	4,163	23.2% (22.0%; 24.6%)	9.2% (8.3%; 10.2%)	4.7% (4.1%; 5.5%)	3.2% (2.6%; 3.9%)	2.4% (1.9%; 3.0%)	1.3% (0.9%; 2.1%)
<b>X/NA</b>	1,818	50.2% (47.9%; 52.6%)	35.2% (33.0%; 37.6%)	28.9% (26.8%; 31.3%)	25.5% (23.4%; 27.8%)	23.9% (21.7%; 26.2%)	20.8% (17.8%; 24.1%)

4.2.2. Pancreatic cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total</b>	19,416	41.9% (41.2%; 42.6%)	25.1% (24.5%; 25.8%)	18.7% (18.2%; 19.4%)	15.8% (15.2%; 16.4%)	14.0% (13.4%; 14.6%)	11.5% (10.6%; 12.4%)
<b>Males</b>							
<b>All</b>	9,921	42.2% (41.2%; 43.2%)	25.3% (24.4%; 26.2%)	19.1% (18.3%; 20.0%)	16.2% (15.4%; 17.1%)	14.3% (13.4%; 15.2%)	11.2% (9.8%; 12.7%)
<b>I</b>	611	89.6% (87.0%; 92.4%)	80.3% (76.8%; 84.0%)	73.6% (69.5%; 78.0%)	71.0% (66.5%; 75.8%)	66.2% (61.0%; 71.8%)	62.2% (49.1%; 78.9%)
<b>II</b>	1,257	76.8% (74.3%; 79.3%)	55.6% (52.7%; 58.7%)	42.1% (39.2%; 45.3%)	34.5% (31.5%; 37.7%)	29.0% (26.0%; 32.3%)	19.6% (15.8%; 24.4%)
<b>III</b>	506	73.7% (69.7%; 77.8%)	47.0% (42.6%; 51.9%)	35.2% (30.9%; 40.1%)	28.3% (24.0%; 33.3%)	23.5% (19.0%; 29.0%)	FU<10y
<b>IV</b>	1,203	29.3% (26.7%; 32.0%)	13.7% (11.8%; 15.9%)	8.4% (6.9%; 10.4%)	6.1% (4.8%; 7.9%)	5.2% (3.9%; 6.9%)	2.7% (1.6%; 4.7%)
<b>X/NA</b>	6,355	30.8% (29.7%; 32.0%)	14.5% (13.6%; 15.4%)	10.1% (9.3%; 10.9%)	8.3% (7.5%; 9.2%)	7.4% (6.6%; 8.3%)	5.9% (4.7%; 7.3%)
<b>Females</b>							
<b>All</b>	9,495	41.5% (40.5%; 42.5%)	24.9% (24.0%; 25.8%)	18.4% (17.5%; 19.2%)	15.4% (14.6%; 16.3%)	13.7% (12.9%; 14.6%)	11.7% (10.5%; 12.9%)
<b>I</b>	685	91.4% (89.2%; 93.8%)	83.5% (80.4%; 86.6%)	74.6% (70.9%; 78.4%)	71.5% (67.5%; 75.7%)	67.7% (63.3%; 72.5%)	65.7% (59.3%; 72.8%)
<b>II</b>	1,084	77.5% (75.0%; 80.1%)	53.5% (50.5%; 56.7%)	41.7% (38.7%; 45.0%)	33.9% (30.9%; 37.2%)	29.1% (26.1%; 32.4%)	19.9% (16.0%; 24.8%)
<b>III</b>	370	75.7% (71.3%; 80.4%)	48.1% (43.0%; 53.8%)	28.5% (23.8%; 34.2%)	22.1% (17.5%; 27.8%)	18.3% (13.9%; 24.2%)	18.6% (13.0%; 26.5%)
<b>IV</b>	1,023	31.7% (28.9%; 34.7%)	14.9% (12.8%; 17.3%)	9.0% (7.3%; 11.0%)	6.3% (4.8%; 8.2%)	4.3% (3.0%; 6.0%)	3.2% (2.0%; 5.0%)
<b>X/NA</b>	6,340	29.5% (28.4%; 30.7%)	14.0% (13.1%; 14.9%)	9.2% (8.4%; 10.0%)	7.3% (6.6%; 8.1%)	6.5% (5.8%; 7.3%)	5.9% (4.8%; 7.2%)

4.2.3. Pancreatic cancer survival by stage and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total</b>	19,416	41.9% (41.2%; 42.6%)	25.1% (24.5%; 25.8%)	18.7% (18.2%; 19.4%)	15.8% (15.2%; 16.4%)	14.0% (13.4%; 14.6%)	11.5% (10.6%; 12.4%)
<b>Males</b>							
<b>All</b>	9,921	42.2% (41.2%; 43.2%)	25.3% (24.4%; 26.2%)	19.1% (18.3%; 20.0%)	16.2% (15.4%; 17.1%)	14.3% (13.4%; 15.2%)	11.2% (9.8%; 12.7%)
<b>I</b>	1,152	74.9% (72.2%; 77.6%)	61.9% (58.8%; 65.1%)	58.1% (54.9%; 61.6%)	55.3% (51.8%; 59.2%)	51.9% (48.0%; 56.2%)	49.1% (40.1%; 60.2%)
<b>II</b>	1,832	65.1% (62.8%; 67.4%)	43.5% (41.1%; 46.0%)	31.7% (29.4%; 34.2%)	25.9% (23.7%; 28.3%)	21.6% (19.4%; 24.1%)	14.8% (12.0%; 18.4%)
<b>III</b>	1,175	56.0% (53.1%; 59.0%)	29.3% (26.7%; 32.2%)	19.7% (17.4%; 22.4%)	15.1% (12.8%; 17.7%)	12.4% (10.1%; 15.2%)	12.2% (9.0%; 16.5%)
<b>IV</b>	4,720	23.7% (22.5%; 25.0%)	9.3% (8.4%; 10.2%)	5.1% (4.4%; 5.8%)	3.4% (2.8%; 4.1%)	2.8% (2.3%; 3.4%)	1.5% (1.0%; 2.3%)
<b>X/NA</b>	1,054	34.6% (31.7%; 37.7%)	21.2% (18.7%; 24.0%)	17.1% (14.7%; 19.8%)	15.6% (13.3%; 18.4%)	14.3% (11.8%; 17.4%)	11.5% (8.4%; 15.8%)
<b>Females</b>							
<b>All</b>	9,495	41.5% (40.5%; 42.5%)	24.9% (24.0%; 25.8%)	18.4% (17.5%; 19.2%)	15.4% (14.6%; 16.3%)	13.7% (12.9%; 14.6%)	11.7% (10.5%; 12.9%)
<b>I</b>	1,295	71.4% (68.8%; 74.1%)	59.3% (56.5%; 62.3%)	52.7% (49.7%; 55.9%)	50.6% (47.5%; 54.0%)	48.2% (44.9%; 51.8%)	49.1% (44.4%; 54.2%)
<b>II</b>	1,714	62.1% (59.7%; 64.5%)	39.1% (36.8%; 41.6%)	29.4% (27.2%; 31.8%)	24.1% (21.9%; 26.4%)	20.7% (18.6%; 23.1%)	14.5% (11.7%; 17.9%)
<b>III</b>	1,067	52.9% (49.9%; 56.1%)	27.4% (24.8%; 30.4%)	15.7% (13.4%; 18.2%)	10.3% (8.4%; 12.8%)	8.1% (6.2%; 10.6%)	7.6% (5.5%; 10.6%)
<b>IV</b>	4,351	23.8% (22.6%; 25.2%)	9.5% (8.7%; 10.5%)	5.0% (4.3%; 5.7%)	3.3% (2.7%; 3.9%)	2.4% (1.9%; 3.0%)	1.4% (0.9%; 2.1%)
<b>X/NA</b>	1,077	32.8% (30.0%; 35.8%)	20.6% (18.2%; 23.3%)	16.6% (14.4%; 19.2%)	14.1% (11.9%; 16.6%)	13.3% (11.1%; 16.0%)	11.6% (8.4%; 16.1%)

## 5. CANCER SURVIVAL TRENDS



### 5.1. Pancreatic cancer survival trends: by tumour stage

5.1.1. Pancreatic cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022

Period	Stage	Males				Females			
		N at risk	Net Survival Probability			N at risk	Net Survival Probability		
			1-y (95%CI)	3-y (95%CI)	5-y (95%CI)		1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
<b>2008-2012</b>	<b>All</b>	3,664	35.6% (34.0%; 37.2%)	14.0% (12.9%; 15.3%)	11.0% (10.0%; 12.2%)	3,462	36.6% (35.0%; 38.3%)	14.1% (12.9%; 15.4%)	10.4% (9.4%; 11.6%)
	<b>I</b>	313	70.4% (65.2%; 76.1%)	47.2% (41.4%; 53.7%)	41.6% (35.7%; 48.4%)	303	70.0% (64.8%; 75.6%)	49.3% (43.6%; 55.8%)	43.3% (37.5%; 50.0%)
	<b>II</b>	835	58.3% (55.0%; 61.9%)	23.5% (20.7%; 26.7%)	17.6% (15.0%; 20.6%)	753	56.7% (53.1%; 60.4%)	21.9% (19.1%; 25.2%)	13.6% (11.2%; 16.4%)
	<b>III</b>	279	36.5% (31.1%; 42.7%)	5.9% (3.7%; 9.6%)	4.1% (2.3%; 7.5%)	301	39.4% (34.2%; 45.4%)	4.9% (3.0%; 8.1%)	3.7% (2.0%; 6.7%)
	<b>IV</b>	1,406	19.2% (17.2%; 21.4%)	4.3% (3.3%; 5.5%)	1.9% (1.3%; 2.8%)	1,261	22.4% (20.2%; 24.8%)	4.8% (3.7%; 6.2%)	2.5% (1.7%; 3.6%)
	<b>X/NA</b>	832	27.1% (24.2%; 30.4%)	11.4% (9.3%; 14.0%)	10.8% (8.7%; 13.4%)	845	26.9% (24.0%; 30.2%)	11.7% (9.6%; 14.3%)	10.1% (8.1%; 12.5%)
<b>2013-2017</b>	<b>All</b>	4,485	38.2% (36.8%; 39.7%)	16.1% (15.0%; 17.3%)	11.6% (10.6%; 12.7%)	4,341	39.2% (37.8%; 40.7%)	16.7% (15.6%; 17.9%)	12.8% (11.8%; 13.9%)
	<b>I</b>	359	71.6% (66.8%; 76.8%)	56.9% (51.3%; 63.1%)	51.0% (44.9%; 57.9%)	452	68.8% (64.4%; 73.5%)	52.2% (47.5%; 57.5%)	50.0% (45.1%; 55.5%)
	<b>II</b>	969	64.6% (61.5%; 67.8%)	29.9% (27.0%; 33.2%)	19.2% (16.6%; 22.1%)	937	62.3% (59.2%; 65.6%)	27.9% (25.1%; 31.1%)	20.1% (17.5%; 23.1%)
	<b>III</b>	379	43.1% (38.3%; 48.5%)	9.0% (6.5%; 12.6%)	4.9% (3.0%; 7.9%)	347	48.2% (43.1%; 53.9%)	12.3% (9.2%; 16.4%)	5.7% (3.5%; 9.1%)
	<b>IV</b>	2,088	21.0% (19.3%; 22.9%)	4.5% (3.7%; 5.5%)	2.4% (1.8%; 3.2%)	1,876	21.9% (20.1%; 23.9%)	4.3% (3.4%; 5.3%)	2.0% (1.5%; 2.8%)
	<b>X/NA</b>	694	33.2% (29.8%; 37.0%)	14.5% (11.9%; 17.6%)	11.9% (9.3%; 15.4%)	733	31.8% (28.5%; 35.5%)	14.4% (11.9%; 17.3%)	11.7% (9.3%; 14.7%)
<b>2018-2022</b>	<b>All</b>	5,436	45.5% (44.2%; 46.9%)	21.7% (20.5%; 23.0%)	17.0% (15.6%; 18.4%)	5,154	43.4% (42.0%; 44.8%)	19.8% (18.6%; 21.1%)	13.9% (12.6%; 15.3%)
	<b>I</b>	793	76.4% (73.2%; 79.6%)	58.8% (54.9%; 63.1%)	52.2% (47.0%; 57.9%)	843	72.8% (69.7%; 76.1%)	52.7% (48.9%; 56.8%)	45.0% (40.2%; 50.4%)
	<b>II</b>	863	65.6% (62.3%; 69.0%)	34.0% (30.5%; 37.9%)	25.4% (21.2%; 30.3%)	777	61.8% (58.3%; 65.5%)	31.5% (28.0%; 35.3%)	20.6% (17.0%; 25.0%)

Period	Stage	Males				Females			
		N at risk	Net Survival Probability			N at risk	Net Survival Probability		
			1-y (95%CI)	3-y (95%CI)	5-y (95%CI)		1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	796	62.1% (58.7%; 65.7%)	25.3% (22.1%; 29.0%)	16.9% (13.7%; 20.9%)	720	55.2% (51.6%; 59.0%)	17.4% (14.5%; 20.8%)	9.7% (7.1%; 13.4%)
	IV	2,632	25.8% (24.2%; 27.6%)	5.4% (4.5%; 6.5%)	3.3% (2.5%; 4.4%)	2,475	25.3% (23.6%; 27.1%)	5.4% (4.5%; 6.5%)	2.6% (1.9%; 3.6%)
	X/NA	360	37.3% (32.5%; 42.9%)	22.5% (18.0%; 28.0%)	19.6% (14.8%; 26.0%)	344	34.9% (30.0%; 40.5%)	22.0% (17.7%; 27.5%)	16.1% (11.6%; 22.4%)



## 5.2. Pancreatic cancer survival trends: by tumour type and tumour stage

### 5.2.1. Pancreatic cancer survival trends by tumour type, stage and sex: number at risk and net survival probabilities, 2008-2022

type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
ADC	2008-2012	All	2,877	33.2% (31.5%; 35.0%)	8.8% (7.8%; 9.9%)	5.8% (5.0%; 6.9%)	2,634	34.2% (32.4%; 36.1%)	8.7% (7.7%; 9.9%)	4.9% (4.1%; 5.8%)
		I	181	62.5% (55.5%; 70.5%)	26.5% (20.3%; 34.5%)	18.9% (13.3%; 26.7%)	163	63.3% (56.1%; 71.5%)	32.6% (25.9%; 41.1%)	21.7% (15.8%; 29.8%)
		II	718	57.7% (54.0%; 61.5%)	19.2% (16.4%; 22.4%)	12.4% (10.0%; 15.3%)	645	55.8% (52.0%; 59.9%)	18.7% (15.8%; 22.0%)	9.9% (7.8%; 12.7%)
		III	226	38.6% (32.6%; 45.6%)	5.4% (3.1%; 9.4%)	3.1% (1.5%; 6.7%)	250	40.5% (34.7%; 47.2%)	3.7% (2.0%; 7.0%)	2.6% (1.2%; 5.5%)
		IV	1,109	17.8% (15.7%; 20.2%)	2.0% (1.3%; 3.0%)	0.8% (0.4%; 1.5%)	970	20.5% (18.1%; 23.3%)	2.0% (1.3%; 3.1%)	0.6% (0.3%; 1.4%)
		X/NA	643	22.4% (19.4%; 26.0%)	5.1% (3.6%; 7.3%)	4.6% (3.1%; 6.8%)	606	22.6% (19.4%; 26.3%)	4.4% (3.0%; 6.5%)	2.8% (1.7%; 4.6%)
	2013-2017	All	3,474	35.2% (33.7%; 36.9%)	10.5% (9.5%; 11.6%)	5.6% (4.8%; 6.5%)	3,238	38.3% (36.7%; 40.1%)	11.3% (10.3%; 12.5%)	7.0% (6.2%; 8.0%)
		I	151	57.0% (49.4%; 65.9%)	35.3% (27.8%; 44.7%)	23.9% (17.2%; 33.4%)	212	62.3% (55.9%; 69.5%)	34.1% (28.0%; 41.6%)	27.5% (21.7%; 35.0%)
		II	839	64.6% (61.4%; 68.1%)	26.4% (23.4%; 29.8%)	14.6% (12.3%; 17.5%)	804	63.6% (60.3%; 67.1%)	25.8% (22.8%; 29.2%)	17.2% (14.6%; 20.3%)
		III	302	45.9% (40.5%; 52.1%)	8.2% (5.6%; 12.1%)	2.9% (1.5%; 5.8%)	286	48.4% (42.8%; 54.6%)	10.2% (7.1%; 14.4%)	3.9% (2.1%; 7.0%)
		IV	1,707	19.3% (17.5%; 21.3%)	2.6% (1.9%; 3.5%)	0.8% (0.5%; 1.4%)	1,473	22.6% (20.6%; 24.9%)	2.5% (1.8%; 3.5%)	0.8% (0.5%; 1.5%)
		X/NA	475	26.8% (23.0%; 31.2%)	4.6% (3.0%; 7.1%)	2.6% (1.4%; 4.8%)	463	27.3% (23.5%; 31.8%)	4.6% (3.1%; 7.1%)	1.8% (0.9%; 3.7%)
	2018-2022	All	4,066	42.0% (40.5%; 43.6%)	13.4% (12.2%; 14.6%)	8.3% (7.1%; 9.6%)	3,825	41.8% (40.2%; 43.4%)	13.5% (12.3%; 14.7%)	7.7% (6.6%; 9.0%)
		I	413	68.8% (64.2%; 73.8%)	38.5% (33.4%; 44.3%)	29.9% (24.1%; 37.1%)	470	70.3% (66.1%; 74.8%)	40.6% (35.9%; 46.0%)	32.3% (26.8%; 38.8%)
		II	666	63.8% (60.1%; 67.7%)	26.3% (22.7%; 30.5%)	18.2% (14.3%; 23.0%)	582	60.3% (56.4%; 64.6%)	24.6% (21.0%; 28.9%)	12.7% (9.4%; 17.2%)
		III	637	63.4% (59.6%; 67.4%)	20.2% (17.0%; 24.1%)	9.8% (7.0%; 13.8%)	599	58.4% (54.5%; 62.6%)	16.2% (13.2%; 19.9%)	7.8% (5.3%; 11.6%)
		IV	2,126	25.6% (23.8%; 27.6%)	3.4% (2.6%; 4.5%)	1.2% (0.7%; 2.1%)	1,975	26.5% (24.6%; 28.5%)	3.6% (2.7%; 4.7%)	0.9% (0.4%; 1.8%)
		X/NA	224	21.8% (16.9%; 28.1%)	4.2% (2.1%; 8.5%)	2.1% (0.8%; 5.8%)	199	21.4% (16.3%; 28.1%)	5.0% (2.6%; 9.6%)	2.8% (1.1%; 7.0%)
NENs	2008-2012	All	301	83.7% (79.4%; 88.3%)	74.1% (68.7%; 79.9%)	66.5% (60.5%; 73.1%)	247	88.8% (84.7%; 93.0%)	75.6% (70.1%; 81.6%)	68.9% (62.7%; 75.7%)
		I	87	97.0% (92.5%; 101.6%)	94.3% (87.7%; 101.4%)	92.4% (84.1%; 101.6%)	74	98.0% (94.3%; 102.0%)	94.1% (87.8%; 100.9%)	96.2% (89.7%; 103.1%)

type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	53	96.5% (90.4%; 103.0%)	93.5% (84.3%; 103.7%)	91.6% (80.1%; 104.8%)	33	N<50	N<50	N<50
		III	6	N<50	N<50	N<50	3	N<50	N<50	N<50
		IV	91	61.6% (52.2%; 72.6%)	41.0% (31.7%; 52.9%)	19.8% (12.7%; 30.8%)	73	72.4% (62.6%; 83.6%)	45.0% (34.6%; 58.5%)	26.8% (17.8%; 40.3%)
		X/NA	64	86.4% (77.7%; 96.0%)	79.9% (68.9%; 92.5%)	77.6% (65.6%; 91.9%)	64	93.4% (87.0%; 100.3%)	85.9% (76.6%; 96.3%)	85.7% (75.7%; 97.2%)
	<b>2013-2017</b>	All	383	82.9% (78.9%; 87.0%)	68.7% (63.7%; 74.1%)	67.4% (61.9%; 73.4%)	365	87.7% (84.2%; 91.3%)	79.8% (75.3%; 84.5%)	76.5% (71.4%; 81.9%)
		I	125	94.2% (89.5%; 99.3%)	89.8% (82.8%; 97.3%)	91.0% (82.8%; 100.1%)	151	97.8% (94.9%; 100.7%)	95.0% (90.4%; 99.8%)	98.2% (93.2%; 103.4%)
		II	56	87.5% (78.7%; 97.2%)	83.7% (73.0%; 96.0%)	84.4% (72.4%; 98.3%)	53	83.9% (74.4%; 94.7%)	76.4% (65.1%; 89.6%)	70.6% (58.1%; 85.7%)
		III	13	N<50	N<50	N<50	11	N<50	N<50	N<50
		IV	116	67.0% (58.8%; 76.5%)	38.2% (30.0%; 48.7%)	29.7% (22.0%; 40.2%)	81	66.3% (56.6%; 77.6%)	46.1% (36.1%; 58.7%)	30.9% (21.9%; 43.5%)
		X/NA	73	84.3% (75.8%; 93.7%)	69.1% (58.0%; 82.2%)	72.2% (60.4%; 86.4%)	69	94.5% (88.5%; 100.9%)	87.9% (78.8%; 98.2%)	87.0% (75.8%; 99.8%)
	<b>2018-2022</b>	All	622	85.9% (82.9%; 88.9%)	78.2% (74.2%; 82.4%)	75.5% (69.7%; 81.7%)	456	87.2% (84.0%; 90.5%)	78.2% (73.8%; 82.7%)	66.9% (60.5%; 73.9%)
		I	220	97.3% (94.4%; 100.4%)	100.3% (96.4%; 104.2%)	99.9% (92.5%; 108.0%)	185	96.0% (92.7%; 99.4%)	90.2% (84.5%; 96.2%)	79.9% (69.6%; 91.8%)
		II	106	95.9% (91.1%; 100.9%)	87.8% (78.5%; 98.2%)	86.0% (69.1%; 107.1%)	80	93.9% (88.2%; 99.9%)	87.7% (79.2%; 97.1%)	76.5% (63.6%; 92.2%)
		III	77	100.0% (96.4%; 103.7%)	89.2% (79.7%; 99.8%)	95.5% (85.3%; 106.8%)	29	N<50	N<50	N<50
		IV	173	60.2% (53.1%; 68.2%)	38.7% (31.2%; 48.0%)	32.8% (24.8%; 43.4%)	118	69.7% (61.7%; 78.8%)	49.7% (40.8%; 60.5%)	36.2% (26.5%; 49.5%)
		X/NA	46	N<50	N<50	N<50	44	N<50	N<50	N<50
<b>Other and unspecified</b>	<b>2008-2012</b>	All	487	19.9% (16.5%; 23.9%)	8.1% (5.9%; 11.2%)	7.5% (5.3%; 10.6%)	582	25.4% (22.0%; 29.3%)	12.6% (10.0%; 15.9%)	10.8% (8.3%; 14.0%)
		I	45	N<50	N<50	N<50	66	55.3% (44.0%; 69.6%)	41.2% (29.7%; 57.2%)	38.5% (26.8%; 55.3%)
		II	64	34.2% (24.1%; 48.5%)	14.3% (7.6%; 26.8%)	14.5% (7.5%; 27.9%)	75	46.0% (35.6%; 59.5%)	23.0% (14.6%; 36.0%)	20.2% (12.2%; 33.2%)
		III	47	N<50	N<50	N<50	48	N<50	N<50	N<50
		IV	206	8.2% (5.1%; 12.9%)	0.5% (0.1%; 2.5%)	FU<5y	218	13.8% (9.9%; 19.4%)	3.7% (1.8%; 7.6%)	2.7% (1.2%; 6.5%)
		X/NA	125	20.7% (14.6%; 29.4%)	8.7% (4.9%; 15.7%)	8.6% (4.6%; 15.8%)	175	17.8% (12.9%; 24.7%)	10.1% (6.3%; 16.2%)	7.9% (4.5%; 13.6%)
	<b>2013-2017</b>	All	633	27.4% (24.0%; 31.3%)	14.8% (12.0%; 18.3%)	10.6% (7.9%; 14.3%)	743	19.4% (16.7%; 22.6%)	9.1% (7.2%; 11.7%)	6.8% (5.0%; 9.3%)
		I	83	64.0% (53.7%; 76.4%)	46.8% (35.6%; 61.6%)	40.2% (28.3%; 57.0%)	89	35.4% (26.4%; 47.4%)	23.3% (15.5%; 35.2%)	22.0% (14.0%; 34.5%)

type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	75	45.9% (35.5%; 59.4%)	28.3% (19.0%; 42.0%)	20.7% (12.1%; 35.4%)	81	34.7% (25.4%; 47.2%)	16.8% (10.1%; 27.9%)	15.3% (8.6%; 27.3%)
		III	64	20.7% (12.7%; 33.7%)	FU<3y	FU<3y	50	39.5% (27.8%; 56.2%)	8.4% (3.4%; 21.0%)	FU<5y
		IV	265	11.9% (8.5%; 16.6%)	2.3% (1.0%; 5.3%)	0.5% (0.1%; 2.5%)	322	7.3% (5.0%; 10.9%)	2.0% (0.9%; 4.2%)	0.3% (0.1%; 1.6%)
		X/NA	146	28.2% (21.5%; 37.0%)	19.0% (12.9%; 28.1%)	12.1% (6.4%; 23.0%)	201	20.6% (15.6%; 27.3%)	11.6% (7.6%; 17.7%)	8.9% (5.2%; 15.1%)
	<b>2018-2022</b>	All	759	31.7% (28.4%; 35.4%)	21.0% (17.9%; 24.6%)	17.7% (14.2%; 22.1%)	879	27.7% (24.8%; 31.0%)	17.6% (14.9%; 20.7%)	14.4% (11.1%; 18.5%)
		I	163	66.4% (58.9%; 74.8%)	54.9% (46.3%; 65.1%)	46.8% (35.1%; 62.4%)	189	56.4% (49.3%; 64.5%)	47.3% (39.3%; 56.8%)	46.7% (36.5%; 59.7%)
		II	91	43.7% (34.2%; 55.7%)	29.7% (20.6%; 42.9%)	16.0% (8.3%; 30.9%)	115	46.9% (38.2%; 57.6%)	27.3% (19.5%; 38.4%)	22.9% (14.4%; 36.5%)
		III	82	16.7% (10.1%; 27.7%)	7.0% (3.1%; 16.0%)	4.0% (1.1%; 14.3%)	92	22.7% (15.5%; 33.3%)	4.6% (1.7%; 12.3%)	1.6% (0.3%; 7.8%)
		IV	333	9.3% (6.6%; 13.1%)	1.6% (0.7%; 3.8%)	1.7% (0.7%; 4.0%)	382	5.7% (3.8%; 8.6%)	0.5% (0.1%; 2.0%)	FU<5y
		X/NA	90	53.6% (43.6%; 65.8%)	36.1% (25.7%; 50.8%)	38.2% (26.5%; 55.1%)	101	40.5% (31.6%; 52.0%)	29.3% (20.6%; 41.7%)	16.8% (7.9%; 35.6%)

## 6. CANCER MORTALITY



### 6.1. Pancreatic cancer mortality: by region

6.1.1. Pancreatic cancer mortality\* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR]																				ESR2013 (95%CI)		
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages	
Males																							
<b>Belgium</b>	0	0	0	0	0	0	1	3	5	13	32	56	100	114	163	156	124	86	37	9	899	17.6	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.8]	[1.3]	[3.4]	[8.0]	[13.9]	[27.5]	[37.2]	[61.5]	[89.6]	[94.9]	[110.7]	[131.8]	[165.0]	[15.8]	(16.5; 18.8)	
Brussels	0	0	0	0	0	0	0	0	1	4	5	2	8	8	13	8	13	6	4	0	72	19.7	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[9.2]	[12.5]	[5.9]	[29.3]	[38.5]	[77.8]	[69.6]	[153.8]	[118.7]	[183.9]	[0.0]	[12.0]	(15.0; 24.3)
Flanders	0	0	0	0	0	0	1	2	2	4	13	26	47	61	100	97	66	55	25	5	504	15.8	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.0]	[0.9]	[1.9]	[5.6]	[10.6]	[21.3]	[32.5]	[61.8]	[85.0]	[76.5]	[106.4]	[136.4]	[139.6]	[15.3]	(14.4; 17.2)	
Wallonia	0	0	0	0	0	0	0	1	2	5	14	28	45	45	50	51	45	25	8	4	323	21.0	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[1.7]	[4.1]	[11.3]	[22.4]	[39.2]	[46.0]	[57.9]	[105.1]	[125.2]	[119.4]	[105.6]	[284.5]	[18.1]	(18.7; 23.4)	
Females																							
<b>Belgium</b>	0	0	0	0	0	0	1	1	2	12	25	43	74	106	169	149	170	158	70	25	1,005	15.2	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.5]	[3.2]	[6.4]	[10.7]	[19.9]	[32.5]	[57.0]	[69.9]	[91.9]	[116.9]	[105.6]	[130.0]	[17.2]	(14.3; 16.2)	
Brussels	0	0	0	0	0	0	0	0	0	1	4	2	4	10	6	10	13	9	12	1	72	13.7	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.5]	[10.8]	[6.0]	[13.5]	[40.8]	[27.8]	[61.5]	[94.9]	[88.6]	[209.1]	[51.1]	[11.6]	(10.5; 16.9)	

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Flanders	0	0	0	0	0	0	1	0	2	6	11	18	49	64	99	81	117	90	41	16	595	14.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.9]	[2.9]	[4.8]	[7.5]	[22.2]	[33.1]	[56.9]	[60.8]	[100.8]	[105.9]	[102.2]	[142.5]	[17.7]	(13.6; 16.0)
Wallonia	0	0	0	0	0	0	0	1	0	5	10	23	21	32	64	58	40	59	17	8	338	16.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[4.1]	[8.1]	[18.0]	[17.3]	[29.4]	[63.5]	[91.0]	[72.5]	[147.3]	[83.2]	[132.4]	[18.1]	(14.7; 18.3)

## 7. CANCER MORTALITY TRENDS



### 7.1. Pancreatic cancer mortality trends: by region

7.1.1. Pancreatic cancer mortality\* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	<b>N</b>	679	723	682	728	767	707	796	795	788	823	788	815	856	897	946	843	893	899		
	<b>CR</b>	13.3	14.1	13.3	14.1	14.7	13.4	15.0	14.8	14.6	15.1	14.4	14.8	15.5	16.1	16.9	15.0	15.8	15.8		
	<b>ESR2013</b>	18.3	18.7	17.7	18.3	19.1	17.2	18.3	18.6	17.7	18.3	17.1	17.4	18.1	18.8	19.4	17.0	17.5	17.6	-0.2 (-0.5; 0.2)	2004-2021
Brussels	<b>N</b>	56	58	58	66	81	60	61	63	68	61	57	69	73	62	67	61	63	72		
	<b>CR</b>	11.7	12.0	11.8	13.3	16.0	11.6	11.6	11.6	12.3	10.9	10.1	12.0	12.6	10.6	11.4	10.3	10.5	12.0		
	<b>ESR2013</b>	17.8	17.9	18.2	21.2	26.6	19.2	17.8	18.6	21.0	17.6	16.3	19.6	20.6	17.8	17.8	16.9	17.0	19.7	-0.5 (-1.6; 0.6)	2004-2021
Flanders	<b>N</b>	375	422	403	407	447	423	468	461	452	491	446	477	486	535	584	540	546	504		
	<b>CR</b>	12.6	14.2	13.4	13.5	14.7	13.8	15.2	14.8	14.4	15.6	14.1	15.0	15.2	16.6	18.0	16.6	16.6	15.3		
	<b>ESR2013</b>	16.7	17.7	17.2	16.5	18.0	16.4	17.6	17.3	16.1	17.6	15.7	16.3	16.5	18.0	19.3	17.3	17.2	15.8	0.0 (-0.5; 0.5)	2004-2021
Wallonia	<b>N</b>	248	243	221	255	239	224	267	271	268	271	285	269	297	300	295	242	284	323		
	<b>CR</b>	15.1	14.7	13.3	15.3	14.2	13.3	15.7	15.8	15.5	15.6	16.4	15.4	16.9	17.0	16.7	13.6	15.9	18.1		
	<b>ESR2013</b>	21.7	21.0	18.7	21.1	19.0	18.3	20.0	21.2	20.2	20.1	20.1	19.2	20.7	20.9	19.8	16.2	18.5	21.0	-0.4 (-1.1; 0.3)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Pancreatic cancer mortality\* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	<b>N</b>	630	731	735	740	749	737	806	854	799	839	859	895	855	947	901	946	960	1,005		
	<b>CR</b>	11.9	13.7	13.7	13.7	13.8	13.4	14.6	15.3	14.2	14.8	15.1	15.7	14.9	16.5	15.6	16.3	16.5	17.2		
	<b>ESR2013</b>	11.8	13.6	13.3	13.4	13.1	12.8	14.0	14.4	13.3	13.9	14.1	14.4	13.7	15.0	14.2	14.7	14.6	15.2	1.0 (0.6; 1.3)	2004-2021
Brussels	<b>N</b>	62	74	79	65	62	95	69	65	85	81	71	75	70	77	75	88	55	72		
	<b>CR</b>	11.9	14.1	14.9	12.2	11.4	17.2	12.3	11.3	14.5	13.7	11.9	12.4	11.5	12.6	12.3	14.3	8.9	11.6		
	<b>ESR2013</b>	12.4	15.0	15.2	13.4	11.9	18.5	13.6	12.9	16.3	14.9	13.6	14.2	13.6	15.8	14.7	16.0	10.6	13.7	-0.1 (-1.4; 1.2)	2004-2021
Flanders	<b>N</b>	346	407	415	408	433	427	468	473	456	462	485	497	506	538	533	556	591	595		
	<b>CR</b>	11.3	13.3	13.5	13.2	13.9	13.6	14.8	14.8	14.2	14.3	14.9	15.2	15.4	16.3	16.1	16.7	17.6	17.7		
	<b>ESR2013</b>	11.2	13.1	12.9	12.6	13.0	12.6	13.8	13.5	12.9	13.0	13.4	13.6	13.5	14.1	13.8	14.4	14.8	14.8	1.0 (0.7; 1.4)	2004-2021
Wallonia	<b>N</b>	222	250	241	267	254	215	269	316	258	296	303	323	279	332	293	302	314	338		
	<b>CR</b>	12.8	14.3	13.7	15.1	14.3	12.0	15.0	17.4	14.2	16.2	16.5	17.6	15.1	17.9	15.8	16.3	16.9	18.1		
	<b>ESR2013</b>	12.8	14.2	13.5	14.8	13.8	11.6	14.4	16.6	13.3	15.2	15.5	16.2	14.1	16.7	14.5	14.9	15.2	16.5	1.0 (0.3; 1.8)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

\*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2024